Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Sowell

Neurology Lenoir, NC Medical Doctor

NPI 1508810029 CMS profile 576551

2202 Nighthawk Ridge Ct, Lenoir, NC 28645

Open in the dashboard

General payments

$1,411

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Sowell of Lenoir, NC is reported in the CMS Open Payments database as having received $1,411 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $263 14
2024 General $305 13
2023 General $330 17
2022 General $86 5
2021 General $225 15
2020 General $94 7
2019 General $108 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Sowell
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to James Sowell were reported at $263. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year James Sowell Neurology median Middle half National median
2019 $108 $474 $118–$2,177 $163
2020 $94 $367 $82–$2,309 $114
2021 $225 $438 $104–$2,547 $132
2022 $86 $442 $103–$2,388 $149
2023 $330 $464 $119–$2,312 $160
2024 $305 $468 $119–$2,323 $164
2025 $263 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $351 20 payments
  2. Alkermes, Inc. $273 14 payments
  3. Teva Pharmaceuticals USA, Inc. $164 10 payments
  4. AbbVie, Inc. $164 11 payments
  5. Janssen Pharmaceuticals, Inc $161 10 payments
  6. AstraZeneca Pharmaceuticals LP $91 1 payment
  7. Indivior Inc. $80 5 payments
  8. E.R. Squibb & Sons, L.L.C. $59 3 payments
  9. Allergan Inc. $30 1 payment
  10. Neurocrine Biosciences, Inc. $25 2 payments
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,381 77 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. LYBALVI $273 14 payments
  2. ARISTADA Cns $273 14 payments
  3. ARISTADA Cns $273 14 payments
  4. ARISTADA Cns $273 14 payments
  5. ARISTADA Cns $273 14 payments
  6. ABILIFY ASIMTUFII $203 10 payments
  7. ABILIFY MAINTENA $190 12 payments
  8. VRAYLAR $164 11 payments
  9. INVEGA SUSTENNA $148 9 payments
  10. UZEDY $109 6 payments
  11. Other $653 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

2,009

Median for Psychiatry & Neurology: 100

Drug cost

$746,478

Median for Psychiatry & Neurology: $2,986

Branded share of claims

19.5%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 111 $354,747
Invega Trinza Paliperidone Palmitate Brand 20 $169,878
Abilify Maintena Aripiprazole Brand 33 $99,362
Vraylar Cariprazine Hcl Brand 29 $46,718
Aristada Aripiprazole Lauroxil Brand 11 $38,823
Paliperidone Er Paliperidone Brand 32 $3,594
Lurasidone Hcl Generic 26 $2,675
Clozapine Generic 35 $2,394
Divalproex Sodium Er Divalproex Sodium Brand 56 $1,942
Haloperidol Decanoate Generic 23 $1,861

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $91
$91 — —
ARISTADA
  • Alkermes, Inc. $61
$61 11 —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $43
$43 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $32
$32 33 —
VRAYLAR
  • AbbVie, Inc. $18
$18 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record